Epoch Biosciences - Ownership and Business Overview

Life ScienceCompany

Epoch Biosciences Ownership

Who owns Epoch Biosciences?

Epoch Biosciences is owned by Nanogen. It was acquired on December 17, 2004.

Was Epoch Biosciences formerly PE-backed?

Yes. Epoch Biosciences was formerly owned by 1 private investor.

Epoch Biosciences Business Overview

Where is Epoch Biosciences headquartered?

Epoch Biosciences is headquartered in Bothell, Washington.

What sector is Epoch Biosciences in?

Epoch Biosciences is a life science company.

When was Epoch Biosciences founded?

Epoch Biosciences was founded in 1985.

Life Science M&A Summary in 2004

Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2004. The largest life science acquisition in 2004 was Sicor - which was acquired by Teva Pharmaceutical Industries for $3.4B.

Join Mergr to view all 52 acquisitions of life science companies in 2004, including 12 acquisitions by private equity firms, and 40 by strategics.

Epoch Biosciences, Inc.

21720 23rd Drive SE, Suite 150,
Bothell, Washington 98021
United States,
(425) 482-5555

Epoch Biosciences, Inc. is a biotech company focused on development and commercialization of proprietary nucleic acid chemistries for research and diagnostic applications.

 Subscribe to unlock this and 202,409
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 4.6K Private Equity Firms
  • 194K M&A Transactions
  • 198K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.